Matrix Asset Advisors Inc. NY Purchases New Position in Humana Inc. (NYSE:HUM)

Matrix Asset Advisors Inc. NY acquired a new position in shares of Humana Inc. (NYSE:HUM) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 6,598 shares of the insurance provider’s stock, valued at approximately $1,674,000.

Several other hedge funds have also recently bought and sold shares of HUM. Creative Financial Designs Inc. ADV increased its stake in shares of Humana by 244.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 61 shares during the period. Atwood & Palmer Inc. bought a new position in Humana during the 3rd quarter worth $29,000. Ashton Thomas Securities LLC bought a new position in Humana during the 3rd quarter worth $31,000. Your Advocates Ltd. LLP lifted its holdings in shares of Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares in the last quarter. Finally, LRI Investments LLC grew its stake in shares of Humana by 1,021.4% in the third quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock valued at $50,000 after acquiring an additional 143 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have weighed in on HUM shares. UBS Group dropped their price objective on shares of Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, October 4th. TD Cowen boosted their price target on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Wells Fargo & Company lowered their price objective on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Morgan Stanley upped their target price on Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Finally, KeyCorp began coverage on Humana in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. Nineteen research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $297.68.

Humana Stock Performance

Shares of Humana stock opened at $297.97 on Tuesday. The business has a 50-day simple moving average of $274.39 and a 200 day simple moving average of $304.27. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market capitalization of $35.88 billion, a price-to-earnings ratio of 26.39, a PEG ratio of 2.15 and a beta of 0.55.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. On average, research analysts anticipate that Humana Inc. will post 16.11 earnings per share for the current fiscal year.

Insider Buying and Selling at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.32% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.